01—Abstract
Summary
Summary of the 8-K filed November 5, 2025. Cited figures are marked; the original filing is the authoritative source.
Revolution Medicines, Inc. (Nasdaq: RVMD) reported financial results for the quarter ended September 30, 2025, and provided a corporate progress update.
Research and development expenses were $262.5 milliona for the quarter, up from $151.8 million a year earlier, driven by clinical trial and manufacturing costs for daraxonrasib, zoldonrasib and elironrasib, plus personnel and stock-based compensation. General and administrative expenses rose to $52.8 million from $24.0 million, and the company posted a net loss of $305.2 million, compared with $156.3 million in the prior-year quarter. For the nine months ended September 30, 2025, net loss was $766.4 million.
The company ended the quarter with cash, cash equivalents and marketable securities of $1.93 billionb, including the first $250 million royalty monetization tranche received in June 2025 from its Royalty Pharma partnership, with an additional $1.75 billion in future committed capital under that arrangement. The company reiterated its full-year 2025 GAAP net loss guidance of $1.03 billion to $1.09 billion, including estimated non-cash stock-based compensation of $115 million to $130 million. On the clinical front, the company said it is winding down global enrollment in the RASolute 302 Phase 3 trial of daraxonrasib in previously treated pancreatic ductal adenocarcinoma (PDAC), with data readout expected in 2026.
It has initiated RASolute 304, a Phase 3 adjuvant PDAC trial, and expects to initiate RASolute 303 in first-line metastatic PDAC this year. Daraxonrasib has received FDA Breakthrough Therapy Designation, Orphan Drug Designation and a Commissioner's National Priority Voucher.
02—Key points
Key Highlights
- Net loss of $305.2 million for Q3 2025, versus $156.3 million in Q3 2024; nine-month net loss of $766.4 million.
- R&D expenses rose to $262.5 million from $151.8 million, and G&A expenses rose to $52.8 million from $24.0 million, citing clinical, manufacturing, personnel and stock-based compensation costs.
- Cash, cash equivalents and marketable securities were $1.93 billion at September 30, 2025, including the first $250 million Royalty Pharma tranche, with $1.75 billion in additional committed capital remaining.
- Full-year 2025 GAAP net loss guidance reiterated at $1.03 billion to $1.09 billion.
- RASolute 302 (daraxonrasib, previously treated PDAC) is winding down enrollment with data readout expected in 2026; RASolute 304 adjuvant PDAC Phase 3 has been initiated and RASolute 303 first-line metastatic PDAC is expected to start this year.
- Zoldonrasib registrational trial in first-line metastatic PDAC expected to start in the first half of 2026; RMC-5127 (RAS(ON) G12V-selective) Phase 1 planned for Q1 2026.
- Total assets were $2.25 billion and total liabilities were $655.0 million at September 30, 2025, versus stockholders' equity of $1.60 billion.
03—Questions
Frequently Asked Questions
Why did operating expenses increase so significantly this quarter?
R&D expenses increased to $262.5 million from $151.8 million, primarily due to higher clinical trial and manufacturing expenses for daraxonrasib, zoldonrasib and elironrasib, along with personnel and stock-based compensation from additional headcount. G&A expenses rose to $52.8 million from $24.0 million, reflecting personnel costs, commercial preparation activities and increased legal expenses.
How much cash does the company have, and what additional funding is available?
Cash, cash equivalents and marketable securities totaled $1.93 billion at September 30, 2025, down from $2.29 billion at December 31, 2024. This includes the $250 million first royalty monetization tranche received in June 2025 from Royalty Pharma, and the filing states there remains an additional $1.75 billion in future committed capital under that arrangement.
What is the status of the key daraxonrasib pivotal trials?
RASolute 302 in previously treated metastatic PDAC is winding down enrollment globally, with an expected data readout in 2026. RASolute 304, an adjuvant resectable PDAC Phase 3 trial, has been initiated, and RASolute 303 in first-line metastatic PDAC is expected to be initiated this year. RASolve 301 in previously treated NSCLC is enrolling in the U.S., Europe and Japan.
What is the company's full-year 2025 loss outlook?
The company reiterated its full-year 2025 GAAP net loss guidance of between $1.03 billion and $1.09 billion, which includes estimated non-cash stock-based compensation expense of between $115 million and $130 million.
04—Continue